Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

The webcast will be broadcast over the interne Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, ...

MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing ...

AMG 133 is a bispecific molecule that ... with obesity and without diabetes, according to Amgen. The drug was given as a subcutaneous injection every four weeks in the study, and showed a clear ...

Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...